接受三线及以上系统治疗的复发或难治性滤泡性淋巴瘤患者的治疗模式与结局(LEO CReWE):一项多中心队列研究
该多中心队列研究纳入美国8个学术中心441例复发或难治性滤泡性淋巴瘤患者,分析三线及以上系统治疗的方案分布与结局。中位随访71个月,5年总生存率75%,中位无进展生存期17个月,总缓解率70%。对烷化剂难治者的总缓解率和5年总生存率均低于非难治者。
要点
- 三线及以上治疗异质性大,免疫化疗、抗CD20单药、来那度胺±抗CD20、PI3K抑制剂±抗CD20均有使用。
- 中位随访71个月,5年总生存率75%,中位无进展生存期17个月,总缓解率70%。
- 对烷化剂难治者总缓解率68% vs 77%,5年总生存率72% vs 81%,HR 1.60。
核心结论
- 复发或难治性滤泡性淋巴瘤患者在三线及以上接受异质性治疗,当代疗法缓解率高但持续时间短。
- 这些数据识别出滤泡性淋巴瘤患者尤其是对烷化剂难治者的未满足需求,并可能为评估新疗法的临床试验提供参照依据。
研究设计与样本
- 多中心队列研究,基于LEO队列研究(NCT02736357)和LEO联盟,纳入美国8个学术中心的数据。
- 筛选933例滤泡性淋巴瘤患者,最终纳入441例,诊断时间在2002年3月6日至2018年7月20日之间。
- 纳入标准为年龄至少18岁、非转化型1-3a级滤泡性淋巴瘤、既往接受过抗CD20抗体和烷化剂后接受三线及以上系统治疗。
- 主要分析指标治疗定义为患者在接受至少两种包含烷化剂和抗CD20治疗的既往系统治疗后接受的第一线系统治疗。
- 主要终点为总缓解率、无进展生存期和总生存期。
主要发现
- 指标治疗包括免疫化疗(n=133)、抗CD20抗体单药(n=53)、来那度胺±抗CD20(n=37)、磷酸肌醇3-激酶抑制剂±抗CD20(n=25)。
- 441例中57例(13%)接受造血干细胞移植,421例数据完整者中98例(23%)接受临床试验治疗。
- 自指标治疗起中位随访71个月(IQR 64-79),5年总生存率75%(95% CI 70-79),中位无进展生存期17个月(15-19),总缓解率70%(65-74;400例可评估缓解者中280例)。
- 对烷化剂难治者总缓解率170/251(68%)vs 非难治者107/139(77%)。
- 对烷化剂难治者5年总生存率72%(95% CI 66-78)vs 非难治者81%(73-89),HR 1.60(95% CI 1.04-2.46)。
关键数值与推荐
- 总缓解率70%(65-74;280/400例可评估者)。
- 中位无进展生存期17个月(15-19)。
- 5年总生存率75%(95% CI 70-79)。
- 对烷化剂难治者 vs 非难治者:总缓解率68%(170/251)vs 77%(107/139);5年总生存率72%(95% CI 66-78)vs 81%(73-89),HR 1.60(95% CI 1.04-2.46)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Novel therapies for relapsed or refractory follicular lymphoma are commonly evaluated in single-arm studies without formal comparison with other treatments or historical controls. Consequently, rigorously defined treatment outcomes informing expectations for novel therapeutic strategies in this population are sparse. To inform outcome expectations, we aimed to describe treatment patterns, survival outcomes, and duration of response in patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy. METHODS: In this multicentre cohort study, we developed a database of patients with relapsed or refractory follicular lymphoma from eight academic centres in the USA using data collected in the LEO Cohort study (NCT02736357) and the LEO Consortium. For this analysis, eligible patients were aged at least 18 years, had non-transformed grade 1-3a follicular lymphoma, and were receiving systemic therapy in the third line or later after previous therapy with an anti-CD20 antibody and an alkylating agent. Clinical data and patient outcomes were abstracted from medical records by use of a standard protocol. The index therapy for the primary analysis was defined as the first line of systemic therapy after the patient had received at least two previous systemic therapies that included an alkylating agent and an anti-CD20 therapy. The main endpoints of interest were overall response rate, progression-free survival, and overall survival. Outcomes were also evaluated in subsets of clinical interest (index therapy characteristics, patient and disease characteristics, treatment history, and best response assessment). FINDINGS: We screened 933 patients with follicular lymphoma, of whom 441 were included and diagnosed between March 6, 2002, and July 20, 2018. Index therapies included immunochemotherapy (n=133), anti-CD20 antibody monotherapy (n=53), lenalidomide with or without anti-CD20 (n=37), and phosphoinositide 3-kinase inhibitors with or without anti-CD20 (n=25). 57 (13%) of 441 patients received haematopoietic stem-cell transplantation and 98 (23%) of 421 patients with complete data received therapy on clinical trials. After a median follow-up of 71 months (IQR 64-79) from index therapy, 5-year overall survival was 75% (95% CI 70-79), median progression-free survival was 17 months (15-19), and the overall response rate was 70% (65-74; 280 of 400 patients evaluable for response). Patients who were refractory to therapy with an alkylating agent had a lower overall response rate (170 [68%] of 251 patients vs 107 [77%] of 139 patients) and a significantly lower 5-year overall survival (72%, 95% CI 66-78 vs 81%, 73-89; hazard ratio 1·60, 95% CI 1·04-2·46) than patients who were not refractory to therapy with an alkylating agent. INTERPRETATION: Patients with relapsed or refractory follicular lymphoma receive heterogeneous treatments in the third-line setting or later. We observed high response rates to contemporary therapies that were of short duration. These data identify unmet needs among patients with follicular lymphoma, especially those who are refractory to alkylating agents, and might provide evidence by which clinical trials evaluating novel treatments could be assessed. FUNDING: Genentech and the National Cancer Institute.
引用
- Casulo C, Larson MC, Lunde JJ, et al. Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study. Lancet Haematol. 2022. PMID: 35358443. doi:10.1016/S2352-3026(22)00033-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。